Pfizer Inc. 2015 Form 10-K Summary
Business context and reporting period
Pfizer is a global biopharmaceutical company with Innovative Products and Established Products businesses. This annual report covers the fiscal year ended December 31, 2015; it is not a standalone fourth-quarter report.
Pfizer acquired Hospira on September 3, 2015, for approximately $16.1 billion in cash ($15.7 billion net of cash acquired). Hospira’s operations are included in the Established Products business. Pfizer also announced a definitive agreement to combine with Allergan in a transaction valued at approximately $160 billion, with completion expected in the second half of 2016, subject to approvals and other conditions.
Financial performance, liquidity and capital allocation
The supplied filing text incorporates the financial statements and much of the Management’s Discussion and Analysis by reference, but does not include clear values for total revenue, net income, operating cash flow, margins, debt, or cash and short-term investments. Accordingly, year-over-year financial results and liquidity ratios cannot be summarized reliably from this text.
- International operations generated $27.1 billion, or 56% of 2015 revenue. Japan was Pfizer’s largest national market outside the U.S.
- Seven biopharmaceutical products and alliance revenues (primarily Eliquis) each exceeded $1 billion and together represented 44% of total 2015 revenue.
- Pfizer paid approximately $5.2 billion under a 2015 accelerated share repurchase agreement. A further approximately $5 billion accelerated repurchase program was anticipated in the first half of 2016, subject to financial results and capital allocation decisions. Remaining share-purchase authorization was approximately $16.4 billion at year-end.
- Management stated that operating cash flows, financial assets, capital-market access and credit facilities supported expected liquidity needs; specific balances and debt metrics are not clear in the supplied text.
Material changes versus the prior comparable period
- Hospira’s acquisition expanded Pfizer’s sterile injectable, infusion-systems and biosimilars businesses; Hospira contributed $1.5 billion of revenue to Pfizer’s 2015 consolidated results after acquisition.
- Pfizer’s product mix continued to face loss-of-exclusivity pressure. Generic Celebrex entered the market in December 2014, and several other products faced patent expirations or challenges.
- In the fourth quarter, Pfizer recorded a foreign-currency loss after determining that certain Venezuela bolivar-denominated monetary assets should be revalued using the SIMADI rate of 200 rather than the prior rate of 6.3; the loss amount is not provided in the supplied text.
- Pfizer stated that the ACA coverage expansion had a negligible impact on 2015 revenue.
Outlook, risks and unusual items
- The Allergan combination remained pending at the report date. Risks include regulatory or shareholder approval delays or failure, integration challenges, transaction and restructuring costs, tax uncertainty, and possible termination payments. In specified circumstances, Pfizer could owe Allergan a termination fee of up to $3.5 billion.
- Key operating risks include generic and biosimilar competition, patent litigation and loss of exclusivity, pricing and reimbursement pressure, dependence on major products, foreign exchange exposure, regulatory and product-safety requirements, manufacturing quality and supply disruptions, and reliance on major wholesalers.
- The top three biopharmaceutical wholesalers accounted for approximately 34% of total 2015 revenue and 74% of U.S. revenue; the largest alone accounted for approximately 14% of total revenue.
- Management reported no serious raw-material shortages or delays in 2015 and none expected in 2016. It also said global economic conditions were not expected to materially affect liquidity or capital resources.
- Environmental expenditures in 2015 included $23 million of environment-related capital expenditures and $144 million of other environment-related expenses.
- Management said disclosure controls were effective and that a material weakness involving intercompany-profit accounting was remediated during the fourth quarter. Hospira’s internal controls, covering $24.2 billion of assets and $1.5 billion of revenue, were excluded from Pfizer’s year-end control assessment.
Most important facts for investors to verify
- Consult the incorporated 2015 Financial Report for audited revenue, earnings, cash flow, margins, debt, liquidity, segment performance and 2016 financial guidance; these values are not clearly provided in the supplied text.
- Review the status, final terms, financing and expected tax treatment of the proposed Allergan combination, including approval conditions and termination provisions.
- Assess Hospira integration progress, manufacturing and quality risks, and realized versus expected acquisition benefits.
- Evaluate the timing and financial impact of product patent expirations, legal challenges, pricing pressure and foreign exchange movements, particularly the Venezuela revaluation.